Pharmasset

2016 Lasker Awards honor scientists for basic and clinical medical research

Monday, September 26, 2016

The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. Kaelin, Peter J. Ratcliffe, and Gregg L. Semenza for basic medical research;Ralf F.W. Bartenschlager, Charles M. Rice, and Michael J. Sofia for clinical research; and Bruce M. Alberts for special achievement. The 2016 Lasker Awards, which carry an honorarium of $250,000 for each category, will be presented on Friday, September 23, in New York City.

[Read More]

Tekmira changes name to Arbutus Biopharma, a hepatitis B solutions company

Wednesday, July 22, 2015

Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.

[Read More]

Turing Pharmaceuticals launched

Wednesday, February 25, 2015

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

[Read More]

Gilead to acquire Pharmasset for $11 billion

Monday, November 21, 2011

Gilead Sciences and Pharmasset have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction, which values Pharmasset at approximately $11 billion, was unanimously approved by Pharmasset’s board of directors. Gilead plans to finance the transaction with cash on hand, bank debt and senior unsecured notes. The company expects the transaction, when completed, to be dilutive to Gilead’s earnings through 2014 and accretive in 2015 and beyond. Further guidance will be provided when the transaction closes, which is expected to be in the first quarter of 2012.

[Read More]

Pharmasset reports fiscal year financial results

Tuesday, November 15, 2011

Princeton, N.J.-based Pharmasset, a clinical stage pharma company that discovers, develops and commercializes drugs to treat viral infections, reported a net loss of $91.2 million, or $1.25 per share, for the fiscal year ended September 30, 2011, compared to a net loss of $66.1 million, or $1.07 per share for fiscal 2010. Revenues were $0.9 million for fiscal year 2011, compared to $1.0 million for fiscal 2010. Revenues during each fiscal year primarily consist of amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue. 

[Read More]

Pharmasset initiates phase IIb QUANTUM trial

Tuesday, September 13, 2011

Pharmasset has begun screening in a phase IIb, international study of PSI-7977 and PSI-938, two nucleotide analog polymerase inhibitors for the treatment of chronic hepatitis C (HCV). The QUANTUM trial will evaluate interferon-free regimens of PSI-7977 400mg QD and PSI-938 300mg QD with and without ribavirin over 12 or 24 weeks in patients with HCV who have not been treated previously. The trial will also evaluate the use of PSI-938 monotherapy.

[Read More]